Literature DB >> 12928403

Membranous cells in nasal-associated lymphoid tissue: a portal of entry for the respiratory mucosal pathogen group A streptococcus.

Hae-Sun Park1, Kevin P Francis, Jun Yu, P Patrick Cleary.   

Abstract

Human tonsils are suspected to be an antibiotic-impervious human reservoir for group A streptococcus. An intranasal infection model in mice and a bioluminescent-tagged strain were used to investigate this possibility. Viable streptococci were predominantly found both intra- and extracellularly in nasal-associated lymphoid tissue (NALT), a human tonsil homologue. Ulex europaeus-1, a membranous (M) cell-specific lectin, identified cells harboring streptococci at the epithelial surface of NALT and blocked bacterial colonization of this tissue. These results suggest that M cells in NALT transport this Gram-positive pathogen across the epithelial layers in a manner similar to those in Peyer's patches, which permit enteric pathogens to invade deeper tissues from the gastrointestinal tract.

Entities:  

Mesh:

Year:  2003        PMID: 12928403     DOI: 10.4049/jimmunol.171.5.2532

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  60 in total

1.  Vaccination against rheumatic heart disease: a review of current research strategies and challenges.

Authors:  Manisha Pandey; Michael R Batzloff; Michael F Good
Journal:  Curr Infect Dis Rep       Date:  2012-08       Impact factor: 3.725

2.  Role of lymphotoxin and homeostatic chemokines in the development and function of local lymphoid tissues in the respiratory tract.

Authors:  Javier Rangel-Moreno; Damian Carragher; Troy D Randall
Journal:  Inmunologia       Date:  2007

Review 3.  Noninvasive biophotonic imaging for studies of infectious disease.

Authors:  Nuria Andreu; Andrea Zelmer; Siouxsie Wiles
Journal:  FEMS Microbiol Rev       Date:  2010-10-19       Impact factor: 16.408

4.  Group A Streptococcus Infection of the Nasopharynx Requires Proinflammatory Signaling through the Interleukin-1 Receptor.

Authors:  Doris L LaRock; Raedeen Russell; Anders F Johnson; Shyra Wilde; Christopher N LaRock
Journal:  Infect Immun       Date:  2020-09-18       Impact factor: 3.441

5.  In vivo activation of naive CD4+ T cells in nasal mucosa-associated lymphoid tissue following intranasal immunization with recombinant Streptococcus gordonii.

Authors:  Donata Medaglini; Annalisa Ciabattini; Anna Maria Cuppone; Caterina Costa; Susanna Ricci; Massimo Costalonga; Gianni Pozzi
Journal:  Infect Immun       Date:  2006-05       Impact factor: 3.441

Review 6.  Tissue tropisms in group A streptococcal infections.

Authors:  Debra E Bessen; Sergio Lizano
Journal:  Future Microbiol       Date:  2010-04       Impact factor: 3.165

7.  Active and passive intranasal immunizations with streptococcal surface protein C5a peptidase prevent infection of murine nasal mucosa-associated lymphoid tissue, a functional homologue of human tonsils.

Authors:  Hae-Sun Park; P Patrick Cleary
Journal:  Infect Immun       Date:  2005-12       Impact factor: 3.441

8.  Intranasal bacteria induce Th1 but not Treg or Th2.

Authors:  M Costalonga; P P Cleary; L A Fischer; Z Zhao
Journal:  Mucosal Immunol       Date:  2008-10-08       Impact factor: 7.313

9.  Different pathologies but equal levels of responsiveness to the recombinant F1 and V antigen vaccine and ciprofloxacin in a murine model of plague caused by small- and large-particle aerosols.

Authors:  Richard J Thomas; Daniel Webber; Aaron Collinge; Anthony J Stagg; Stephen C Bailey; Alejandro Nunez; Amanda Gates; Pramukh N Jayasekera; Rosa R Taylor; Steve Eley; Richard W Titball
Journal:  Infect Immun       Date:  2009-02-02       Impact factor: 3.441

10.  Group A Streptococcus intranasal infection promotes CNS infiltration by streptococcal-specific Th17 cells.

Authors:  Thamotharampillai Dileepan; Erica D Smith; Daniel Knowland; Martin Hsu; Maryann Platt; Peter Bittner-Eddy; Brenda Cohen; Peter Southern; Elizabeth Latimer; Earl Harley; Dritan Agalliu; P Patrick Cleary
Journal:  J Clin Invest       Date:  2015-12-14       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.